This is an AI generated summary. There may be inaccuracies. · The green links below are Amazon affiliate links where summarize.tech may earn a commission.
Summarize another video · Purchase summarize.tech Premium
In the near future, Brazil may see a vaccine for chikungunya that is 98% effective in protecting against the virus. The vaccine was developed by a European laboratory in collaboration with the Instituto Butantan and has already shown high efficacy in clinical trials. The chikungunya virus causes symptoms such as fever, red rashes, and severe body pain, and can lead to long-term complications. Currently, there is no specific treatment for chikungunha, and the current preventive methods have been ineffective. Although the vaccine has been approved in the US, it is still awaiting authorization in Brazil by Anvisa in order to be distributed for free through the SUS system.